Balancing Efficacy, Health Status, and Cost-Effectiveness: A Comparative Study of Desidustat and Erythropoietin in Chronic Kidney Disease Patients on Hemodialysis.

Anemia is a common problem that greatly affects the quality of life and prognosis of those with CKD (chronic kidney disease). The conventional course of treatment has traditionally used ESAs (erythropoiesis-stimulating agents) such as erythropoietin; however, more recent medications, such as Desidustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), may be more advantageous in terms of both efficacy and cost. In this study, CKD patients receiving hemodialysis are compared for efficacy, safety, and cost-effectiveness between Desidustat and erythropoietin treatment.

Central vein stenosis- prevalence, clinical characteristics, outcome and its impact on dialysis access.

Central vein stenosis (CVS) is a complication primarily affecting chronic hemodialysis patients, frequently resulting in vascular access dysfunction and decreased dialysis efficacy. While CVS has a variable mortality rate, its impact on dialysis access is profound, including arm edema, facial swelling, and venous hypertension. We describe the prevalence, clinical presentation, and treatment outcomes of CVS for vascular access in hemodialysis patients.